ID: ALA267434

Max Phase: Preclinical

Molecular Formula: C31H32N4O4

Molecular Weight: 524.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccnc(NCCCC(=O)NCC(=O)NC(CC(=O)O)c2ccc(-c3cccc4ccccc34)cc2)c1

Standard InChI:  InChI=1S/C31H32N4O4/c1-21-15-17-33-28(18-21)32-16-5-10-29(36)34-20-30(37)35-27(19-31(38)39)24-13-11-23(12-14-24)26-9-4-7-22-6-2-3-8-25(22)26/h2-4,6-9,11-15,17-18,27H,5,10,16,19-20H2,1H3,(H,32,33)(H,34,36)(H,35,37)(H,38,39)

Standard InChI Key:  LZXHGKPQGMADDV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 524.62

Molecular Weight (Monoisotopic): 524.2424

AlogP: 4.85

#Rotatable Bonds: 12

Polar Surface Area: 120.42

Molecular Species: ACID

HBA: 5

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 4.42

CX Basic pKa: 7.43

CX LogP: 2.08

CX LogD: 1.81

Aromatic Rings: 4

Heavy Atoms: 39

QED Weighted: 0.20

Np Likeness Score: -0.78

References

1. Goodman SL, Hölzemann G, Sulyok GA, Kessler H..  (2002)  Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.,  45  (5): [PMID:11855984] [10.1021/jm0102598]

2. Adams J, Anderson EC, Blackham EE, Chiu YW, Clarke T, Eccles N, Gill LA, Haye JJ, Haywood HT, Hoenig CR, Kausas M, Le J, Russell HL, Smedley C, Tipping WJ, Tongue T, Wood CC, Yeung J, Rowedder JE, Fray MJ, McInally T, Macdonald SJ..  (2014)  Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.,  5  (11): [PMID:25408832] [10.1021/ml5002079]

Source

Source(1):

• Scientific Literature